{"product_id":"global-3d-bioprinting-market-size-study-forecast-by-component-3d-bioprinters-bioinks-by-application-research-applications-clinical-applications-by-end-userresearch-organizations-and-academic-institutes-biopharmaceutical-companies-hospitals-an","title":"Global 3D Bioprinting Market Size study \u0026 Forecast, by Component (3D Bioprinters, Bioinks) By Application (Research applications, Clinical applications) By End user(Research Organizations and Academic Institutes, Biopharmaceutical companies, Hospitals) an","description":"\u003cp\u003eGlobal 3D Bioprinting Market Size study \u0026amp; Forecast, by Component (3D Bioprinters, Bioinks) By Application (Research applications, Clinical applications) By End user(Research Organizations and Academic Institutes, Biopharmaceutical companies, Hospitals) and Regional Analysis, 2022-2029\u003c\/p\u003e\n\n\u003cp\u003eGlobal 3D Bioprinting Market is valued at approximately USD 1.7 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 15.8% over the forecast period 2022-2029. 3D Bioprinting is a technology where bioinks, mixed with living cells to produce living tissue, bone, blood vessels and organs for use in medical procedures. The 3D Bioprinting market is expanding because of factors such as rising old age population with chronic respiratory disease. and increasing use of 3D bioprinting in pharmaceutical and cosmetology industries.\u003c\/p\u003e\n\n\u003cp\u003eAccording to the World Health Organization, Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide, causing 3.23 million deaths in 2019. Nearly 90% of COPD deaths are of under 70 years of age occur in lower and middle-income countries. Furthermore, in the United States in between 2008 and 2021 the rate of lung transplants per million inhabitants was increased by 4.9.% to 7.7%. Another important component driving space Increasing use of 3D bioprinting in pharmaceutical and cosmetology industries. Moreover, as per Statista the global pharmaceutical market has shown significant growth in recent years. As of end-2021, the total global pharmaceutical market was valued at about 1.42 trillion U.S. dollars. Skincare was the leading category, accounting for about 42 percent of the global market. Furthermore, the global market value for natural cosmetics and personal care expected a positive increase from almost 35 billion dollars in 2021 to roughly 59 billion dollars expected for the year 2031. However, less availability of 3D Bioprinting professional’s stifles market growth throughout the forecast period of 2022-2029.\u003c\/p\u003e\n\n\u003cp\u003eThe key regions considered for the Global 3D Bioprinting Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. Asia Pacific dominated the space in terms of revenue, owing to the rising investment of government in R\u0026amp;D. According to the Statista, China stands is projected to spend 190 and 220 billion U.S. billion dollars in medicine expenditures by 2026. North America is expected to grow significantly during the forecast period, owing to factors such as increasing incorporation of IT in the healthcare industry in the market space.\u003c\/p\u003e\n\n\u003cp\u003eMajor market player included in this report are:\u003c\/p\u003e\n\n\u003cp\u003eBICO Group AB\u003cbr\u003e\nOrganovo Holdings Inc.\u003cbr\u003e\nAllevi, Inc.\u003cbr\u003e\nCollPlant Biotechnologies Ltd.\u003cbr\u003e\nregenHU\u003cbr\u003e\nEnvisionTEC GmbH\u003cbr\u003e\nAspect Biosystems Ltd.\u003cbr\u003e\nAdvanced Solutions Life Sciences, LLC\u003cbr\u003e\nRegenovo Biotechnology Co., Ltd.\u003cbr\u003e\nVivax Bio, LLC\u003c\/p\u003e\n\n\u003cp\u003eRecent Developments in the Market:\u003cbr\u003e\n? In February 2022, CELLINK, and a global leader in developing 3D bioprinting technologies which is expected to bridge the current gap and allow unlimited supply of life saving organs and CollPlant Biotechnologies a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, announced they have signed a collaboration agreement. Under this collaboration, CELLINK’s high-throughput, multi-material extrusion bioprinter will be explored for the development of large-scale production of CollPlant's 3D bioprinted regenerative breast implants, addressing a current market size of $2.8 billion, with 2.2 million procedures performed annually worldwide.\u003cbr\u003e\nGlobal 3D Bioprinting Market Report Scope:\u003cbr\u003e\nHistorical Data 2019-2020-2021\u003cbr\u003e\nBase Year for Estimation 2021\u003cbr\u003e\nForecast period 2022-2029\u003cbr\u003e\nReport Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends\u003cbr\u003e\nSegments Covered Component, Application, End User, Region\u003cbr\u003e\nRegional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World\u003cbr\u003e\nCustomization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional \u0026amp; segment scope*\u003c\/p\u003e\n\n\u003cp\u003eThe objective of the study is to define market sizes of different segments \u0026amp; countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.\u003c\/p\u003e\n\n\u003cp\u003eThe report also caters detailed information about the crucial aspects such as driving factors \u0026amp; challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.\u003c\/p\u003e\n\n\u003cp\u003eThe detailed segments and sub-segment of the market are explained below:\u003cbr\u003e\nBy Component:\u003cbr\u003e\n3D Bioprinters\u003cbr\u003e\nBioinks\u003c\/p\u003e\n\n\u003cp\u003eBy Application:\u003cbr\u003e\nResearch applications\u003cbr\u003e\nClinical applications\u003c\/p\u003e\n\n\u003cp\u003eBy End User:\u003cbr\u003e\nResearch Organizations and Academic Institutes,\u003cbr\u003e\nBiopharmaceutical companies\u003cbr\u003e\nHospitals\u003c\/p\u003e\n\n\u003cp\u003eBy Region:\u003cbr\u003e\nNorth America\u003cbr\u003e\nU.S.\u003cbr\u003e\nCanada\u003cbr\u003e\nEurope\u003cbr\u003e\nUK\u003cbr\u003e\nGermany\u003cbr\u003e\nFrance\u003cbr\u003e\nSpain\u003cbr\u003e\nItaly\u003cbr\u003e\nROE\u003cbr\u003e\nAsia Pacific\u003cbr\u003e\nChina\u003cbr\u003e\nIndia\u003cbr\u003e\nJapan\u003cbr\u003e\nAustralia\u003cbr\u003e\nSouth Korea\u003cbr\u003e\nRoAPAC\u003cbr\u003e\nLatin America\u003cbr\u003e\nBrazil\u003cbr\u003e\nMexico\u003cbr\u003e\nRest of the World\u003c\/p\u003e\n\n\u003cp\u003eCompanies Mentioned\u003c\/p\u003e\n\n\u003cp\u003eBICO Group AB\u003cbr\u003e\nOrganovo Holdings Inc.\u003cbr\u003e\nAllevi, Inc.\u003cbr\u003e\nCollPlant Biotechnologies Ltd.\u003cbr\u003e\nregenHU\u003cbr\u003e\nEnvisionTEC GmbH\u003cbr\u003e\nAspect Biosystems Ltd.\u003cbr\u003e\nAdvanced Solutions Life Sciences, LLC\u003cbr\u003e\nRegenovo Biotechnology Co., Ltd.\u003cbr\u003e\nVivax Bio, LLC\u003c\/p\u003e\n\n\u003cp\u003ePlease note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"February, 2023 \/ 200 Pages \/ MCW16227940","offer_id":47646803493170,"sku":null,"price":5940.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/global-3d-bioprinting-market-size-study-forecast-by-component-3d-bioprinters-bioinks-by-application-research-applications-clinical-applications-by-end-userresearch-organizations-and-academic-institutes-biopharmaceutical-companies-hospitals-an","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}